| 產(chǎn)品編號 | bs-9567R-PE-Cy5.5 |
| 英文名稱 | Rabbit Anti-ANT1+ANT2+ANT3+ANT4/PE-Cy5.5 Conjugated antibody |
| 中文名稱 | PE-Cy5.5標記的腺嘌呤核苷酸轉運蛋白1、2、3、4抗體 |
| 別 名 | ATP carrier protein 1; ADP ATP carrier protein heart/skeletal muscle isoform T1; ADP/ATP translocase 1; ADT1_HUMAN; ANT 1; ANT; ANT1; ATP carrier protein 2; ADP ATP carrier protein heart/skeletal muscle isoform T2; ADP/ATP translocase 2; ADT2_HUMAN; ANT 2; ANT; ATP carrier protein 3; ADP ATP carrier protein heart/skeletal muscle isoform T3; ADP/ATP translocase 3; ADT3_HUMAN; ANT3; ATP carrier protein 4; ADP ATP carrier protein heart/skeletal muscle isoform T4; ADP/ATP translocase 4; ADT4_HUMAN; ANT 4;ANT4. |
| 規(guī)格價格 | 100ul/2980元 購買 大包裝/詢價 |
| 說 明 書 | 100ul |
| 研究領域 | 心血管 細胞生物 神經(jīng)生物學 信號轉導 轉錄調(diào)節(jié)因子 G蛋白偶聯(lián)受體 |
| 抗體來源 | Rabbit |
| 克隆類型 | Polyclonal |
| 交叉反應 | (predicted: Human, Mouse, Rat, Horse, Rabbit, ) |
| 產(chǎn)品應用 | ICC=1:50-200 IF=1:50-200
not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 分 子 量 | 33kDa |
| 性 狀 | Lyophilized or Liquid |
| 濃 度 | 1mg/ml |
| 免 疫 原 | KLH conjugated synthetic peptide derived from human ANT1/2/3/4 |
| 亞 型 | IgG |
| 純化方法 | affinity purified by Protein A |
| 儲 存 液 | 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| 保存條件 | Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C. |
| 產(chǎn)品介紹 |
background: Adenine nucleotide translocator (ANT) and the voltage-dependent anion-selective channel proteins 1 and 2 (VDAC1 and VDAC2) are components of the permeability transition pore complex (PTPC) of the mitochondrial inner and outer membranes, respectively. Formation of PTPCs, the subsequent dissipation of mitochondrial inner membrane potential and release of cytochrome c through the outer mitochondrial membrane are critical events in the early stages of apoptosis. Bax, a proapoptotic protein, has been shown to act upon ANT to induce the dissipation of mitochondrial inner membrane potential. ANT1 has a role in the maintenance of mitochondrial DNA by catalyzing the exchange of ADP and ATP across the mitochondrial inner membrane. Function: Catalyzes the exchange of ADP and ATP across the mitochondrial inner membrane. As part of the mitotic spindle-associated MMXD complex it may play a role in chromosome segregation. Subunit: Found in a complex with ARL2, ARL2BP and SLC25A4. Interacts with ARL2BP (By similarity). Homodimer. Interacts with HIV-1 Vpr. Subcellular Location: Mitochondrion inner membrane; Multi-pass membrane protein. DISEASE: Defects in SLC25A4 are a cause of progressive external ophthalmoplegia with mitochondrial DNA deletions autosomal dominant type 2 (PEOA2) [MIM:609283]. Progressive external ophthalmoplegia is characterized by progressive weakness of ocular muscles and levator muscle of the upper eyelid. In a minority of cases, it is associated with skeletal myopathy, which predominantly involves axial or proximal muscles and which causes abnormal fatigability and even permanent muscle weakness. Ragged-red fibers and atrophy are found on muscle biopsy. A large proportion of chronic ophthalmoplegias are associated with other symptoms, leading to a multisystemic pattern of this disease. Additional symptoms are variable, and may include cataracts, hearing loss, sensory axonal neuropathy, ataxia, depression, hypogonadism, and parkinsonism. Similarity: Belongs to the mitochondrial carrier family. Database links: UniProtKB/Swiss-Prot: P12235.4 UniProtKB/Swiss-Prot: Q9H0C2.1 Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. |
| 1、抗體溶解方法 | |
| 2、抗體修復方式 | |
| 3、常用試劑的配制 | |
| 4、免疫組化操作步驟 | |
| 5、免疫組化問題解答 | |
| 6、Western Blotting 操作步驟 | |
| 7、Western Blotting 問題解答 | |
| 8、關于肽鏈的設計 | |
| 9、多肽的溶解與保存 | |
| 10、酶標抗體效價測定程序 | |
